Original article| Volume 42, 102056, July 2020

Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort


      • Health services must ready themselves to provide DMTs for people with progressive MS.
      • Estimated eligibility rates are helpful to plan resource requirements.
      • Many prevalent cases of progressive MS will require clinical and radiological re-evaluation.
      • The cost of DMT provision will include both drug and service components.



      As disease-modifying therapies become approved for primary progressive multiple sclerosis (PPMS), services must be aligned in readiness.


      In this paper we use population and clinic-based data to estimate eligibility rates for ocrelizumab, and the extent of additional service requirements necessary to ensure its widespread introduction in PPMS.


      Overall population estimates for the incidence and prevalence of people with PPMS who are eligible for ocrelizumab are 1.6 and 4.2 per 100,000 respectively. The majority (87%) of incident cases of PPMS satisfied clinical eligibility criteria for ocrelizumab but lacked radiological evidence of disease activity due to a historical tendency not to routinely monitor using MRI in this group. The majority of prevalent patients did not satisfy clinical eligibility criteria for ocrelizumab, mainly because of advanced disease duration or disability.


      These findings illustrate the fact that there has been a tendency for people with PPMS not to receive routine clinical and radiological monitoring. Additional planning or resources will be required to facilitate contemporary disease re-evaluation and surveillance at a population level.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Harding K.E.
        • Wardle M.
        • Moore P.
        • Tomassini V.
        • Pickersgill T.
        • Ben-shlomo Y.
        • et al.
        Modelling the natural history of primary progressive multiple sclerosis.
        J. Neursol. Neurosurg. Psychiatry. 2015; 86: 13-19
      1. StatsWales [Internet]. [cited 2006 Jul 20]. Available from:

        • Poser C.M.
        • Paty D.W.
        • Scheinberg L.
        • McDonald W.I.
        • Davis F.A.
        • Ebers G.C.
        • et al.
        New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
        Ann. Neurol. 1983; 13 (Mar): 227-231
        • Polman C.H.
        • Reingold S.C.
        • Edan G.
        • Filippi M.
        • Hartung H.-.P.
        • Kappos L.
        • et al.
        Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria.
        Ann. Neurol. 2005; 58 (Dec): 840-846
        • McDonald W.I.
        • Compston A.
        • Edan G.
        • Goodkin D.
        • Hartung H.-.P.
        • Lublin F.D.
        • et al.
        Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis.
        Ann. Neurol. 2001; 50: 121-127
        • Polman C.H.
        • Reingold S.C.
        • Banwell B.
        • Clanet M.
        • Cohen J.A.
        • Filippi M.
        • et al.
        Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
        Ann. Neurol. 2011; 69 (InternetFebAvailable from): 292-302
        • Thompson A.J.
        • Banwell B.L.
        • Barkhof F.
        • Carroll W.M.
        • Coetzee T.
        • Comi G.
        • et al.
        Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
        Lancet Neurol. 2018; (InternetJan 8Available from)